CN105579470B - Il-21结合蛋白和其用途 - Google Patents

Il-21结合蛋白和其用途 Download PDF

Info

Publication number
CN105579470B
CN105579470B CN201480037182.8A CN201480037182A CN105579470B CN 105579470 B CN105579470 B CN 105579470B CN 201480037182 A CN201480037182 A CN 201480037182A CN 105579470 B CN105579470 B CN 105579470B
Authority
CN
China
Prior art keywords
binding protein
antibody
seq
binding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480037182.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105579470A (zh
Inventor
查尔斯·瑞·麦凯
迪玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902377A external-priority patent/AU2013902377A0/en
Application filed by Monash University filed Critical Monash University
Publication of CN105579470A publication Critical patent/CN105579470A/zh
Application granted granted Critical
Publication of CN105579470B publication Critical patent/CN105579470B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480037182.8A 2013-06-27 2014-06-27 Il-21结合蛋白和其用途 Expired - Fee Related CN105579470B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013902377 2013-06-27
AU2013902377A AU2013902377A0 (en) 2013-06-27 A super-agonist monoclonal antibody to human IL-21 and its application in immunomodulation
PCT/AU2014/000673 WO2014205501A1 (en) 2013-06-27 2014-06-27 Il-21 binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
CN105579470A CN105579470A (zh) 2016-05-11
CN105579470B true CN105579470B (zh) 2021-05-25

Family

ID=52140667

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480037182.8A Expired - Fee Related CN105579470B (zh) 2013-06-27 2014-06-27 Il-21结合蛋白和其用途

Country Status (8)

Country Link
US (3) US10077301B2 (enExample)
EP (1) EP3013858B1 (enExample)
JP (1) JP6563389B2 (enExample)
CN (1) CN105579470B (enExample)
AU (1) AU2014302028B2 (enExample)
CA (1) CA2915882C (enExample)
ES (1) ES2898650T3 (enExample)
WO (1) WO2014205501A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205501A1 (en) 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
JP6872756B2 (ja) * 2016-01-12 2021-05-19 国立大学法人千葉大学 抗Ｍｙｌ９抗体
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN119290543B (zh) * 2024-12-13 2025-03-21 天津医科大学总医院空港医院 一种同时检测淋巴组织中il-6、il-21与t细胞cd4表面分子的试剂盒及方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005244942A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
WO2006105538A2 (en) * 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
JP5322653B2 (ja) 2005-11-28 2013-10-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
WO2007109742A2 (en) 2006-03-21 2007-09-27 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
WO2008112543A2 (en) * 2007-03-09 2008-09-18 Wyeth Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences
JP5745274B2 (ja) * 2007-12-07 2015-07-08 ザイモジェネティクス， インコーポレイテッド 抗ヒトｉｌ−２１モノクローナル抗体
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
WO2014205501A1 (en) 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005244942A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
WO2006105538A2 (en) * 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. Søndergaard等.IL-21: roles in immunopathology and cancer therapy.《Tissue Antigens》.2009,第74卷第467–479页. *
Potent antibody therapeutics by design;Paul J. Carter;《NATURE REVIEWS IMMUNOLOGY》;20060407;第6卷;图2及注释 *

Also Published As

Publication number Publication date
US20210002362A1 (en) 2021-01-07
CN105579470A (zh) 2016-05-11
WO2014205501A1 (en) 2014-12-31
CA2915882C (en) 2022-12-06
US20190071497A1 (en) 2019-03-07
EP3013858A1 (en) 2016-05-04
AU2014302028A1 (en) 2016-01-21
AU2014302028B2 (en) 2019-09-19
US20160145332A1 (en) 2016-05-26
CA2915882A1 (en) 2014-12-31
JP2016529213A (ja) 2016-09-23
ES2898650T3 (es) 2022-03-08
EP3013858B1 (en) 2021-07-28
US10787510B2 (en) 2020-09-29
US10077301B2 (en) 2018-09-18
JP6563389B2 (ja) 2019-08-21
EP3013858A4 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
TWI853077B (zh) 新型抗ｃｄ３９抗體
JP7043685B2 (ja) ヒト化抗ヒトｐｄ－１抗体
CN114395048B (zh) Cd3结合抗体
US10787510B2 (en) Methods of treating cancer using an IL-21 agonist
JP6545105B2 (ja) Ｉｌ−１１ｒ結合タンパク質及びその使用
US12037399B2 (en) Anti-Dectin-1 antibodies and methods of use thereof
WO2019179391A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
CN107531784B (zh) 通过多特异性抗体超强力地中和细胞因子和其用途
EP3737694A1 (en) Anti-pd-1 antibodies and methods of treatment
US20210244825A1 (en) Il-21 antibodies
JP6187777B2 (ja) Ｇ−ｃｓｆｒに対する抗体およびその使用
WO2019206095A1 (zh) 针对tim-3的抗体及其用途
JP2023536631A (ja) 多重特異性結合性作用剤およびその使用
WO2019179421A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
HK40015686B (zh) Il-11r结合蛋白及其应用
HK40042102A (en) Anti-avb8 antibodies and compositions and uses thereof
HK40036660A (en) Anti-cd25 for tumour specific cell depletion
HK40036659A (en) Anti-cd25 for tumour specific cell depletion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210525

CF01 Termination of patent right due to non-payment of annual fee